University of Bath
Bath, BA2 7AY, United Kingdom
NCT Number: NCT06668168
Excess weight increases the risk of several diseases including cardiovascular disease, type 2 diabetes, kidney disease and various cancers. There is a need for preventative strategies for obesity-associated disease, especially for people in the overweight and moderately obese ranges where pharmacological intervention may not be suitable.
Low-carbohydrate (ketogenic) diets are popular for weight control. Ketogenic diets increase circulating ketones, which can have favourable effects on cardiometabolic health markers. However, the ketogenic diet has a nutrient composition associated with harms (high-saturated fat/red meat, and low-fibre). The net effects of ketogenic diets on long-term health are unclear. Ketone supplements can increase circulating ketones and could provide benefits of ketosis without needing to adhere to a potentially harmful diet.
Establishing causality between complex exposures (e.g., diet) and long-term outcomes (e.g., disease), is challenging. The MRC & NIHR Review of Nutrition and Human Health Research (2017) highlighted an "overreliance (as opposed to reasonable reliance) on observational studies" as a key barrier to progression in the field of nutrition and health. Randomised controlled trials (RCTs) facilitate causal inference, but for long-term outcomes are expensive, time-consuming, and often suffer from waning adherence. Mendelian randomization (MR) can estimate causal effects subject to key assumptions. A challenge to these assumptions includes complex behavioural exposures (e.g., diet), which could be intercorrelated with causal factors.
Our proposal will address these limitations with a novel combination of study designs to establish causal effects of ketosis (via diet and supplementation) on obesity-associated disease risk in humans.
The investigators will combine a tightly controlled, short-term RCT, with MR to link short-term responses to long-term endpoints. The investigators will examine the circulating (blood) and tissue-specific (adipose) transcriptomic and proteomic responses in the fasted and postprandial state in response to our dietary interventions and translate these to MR by identifying single-nucleotide polymorphisms from genome wide association studies. This approach overcomes limitations of RCTs and MR, as adherence to diets will be confirmed with controlled feeding, and intermediate molecular traits as exposure for MR are less likely to be intercorrelated with causal traits.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Bath, BA2 7AY, United Kingdom
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
25g ketone ester 3x/day. The ketone ester will be a beta-hydroxybutyrate monoester [(R)-3-hydroxybutyl (R)-3-hydroxybutyrate].
Ketogenic diet (<50 g carbohydrate per day)
Time frame: From baseline to week 4
Plasma proteome at week 4 adjusted for baseline values
Time frame: From baseline to week 4
Transcriptome of peripheral blood mononuclear cells at week 4 adjusting for baseline values
Time frame: From baseline to week 4
Transcriptome of subcutaneous abdominal adipose tissue at week 4 adjusting for baseline values
Time frame: From baseline to week 4
Plasma apolipoprotein B concentrations at week 4 adjusted for baseline values.
Time frame: From baseline to week 4
Urinary albumin concentrations at week 4 adjusting for baseline values
Time frame: From baseline to week 4
Plasma fasting glucose concentrations at week 4 adjusting for baseline values
University of Bath
Other
Acronym: KETO-GENETIC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06724172
Body Weight, Chronic Disease
Palo Alto, California, United States
View Trial DetailsNCT07526584
Body Weight, Nutrition
Chapel Hill, North Carolina, United States
View Trial DetailsNCT06996262
Body Weight, Cardiac Disease
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT04652713
Body Weight, Cholesterol Ester Storage Disease
Aarhus, Denmark
View Trial Details